Suggested remit: To appraise the clinical and cost effectiveness of low-dose atropine eye drops within its marketing authorisation for treating myopia in people 3 to 14 years.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Scoping commenced.
Process STA Standard
ID number 6517

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6517 24 March 2025 - 23 April 2025

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
24 March 2025 In progress
12 December 2024 Awaiting development
12 December 2024 Topic selection. .

For further information on our processes and methods, please see our CHTE processes and methods manual